Altimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Altimmune, Inc. (NASDAQ:ALT) has earned a consensus rating of “Moderate Buy” from the eight analysts that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $20.00.

A number of research analysts recently weighed in on ALT shares. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Altimmune in a report on Thursday, November 14th. UBS Group initiated coverage on shares of Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 price target on the stock.

Altimmune Stock Down 1.7 %

Shares of NASDAQ:ALT opened at $8.59 on Friday. Altimmune has a fifty-two week low of $5.28 and a fifty-two week high of $14.84. The firm’s 50-day simple moving average is $7.65 and its 200-day simple moving average is $7.05. The company has a market cap of $610.96 million, a price-to-earnings ratio of -5.54 and a beta of 0.15.

Altimmune (NASDAQ:ALT) last released its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.03. The company had revenue of $0.01 million for the quarter. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same quarter in the previous year, the firm posted ($0.39) EPS. On average, research analysts forecast that Altimmune will post -1.36 EPS for the current year.

Institutional Investors Weigh In On Altimmune

Institutional investors and hedge funds have recently made changes to their positions in the business. Bellevue Group AG grew its holdings in Altimmune by 43.9% during the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock valued at $5,303,000 after buying an additional 263,660 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Altimmune by 542.8% during the second quarter. SG Americas Securities LLC now owns 254,571 shares of the company’s stock valued at $1,693,000 after acquiring an additional 214,968 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Altimmune by 142.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock worth $3,791,000 after purchasing an additional 335,444 shares in the last quarter. Hennion & Walsh Asset Management Inc. acquired a new position in Altimmune in the 2nd quarter valued at about $860,000. Finally, Los Angeles Capital Management LLC acquired a new position in Altimmune in the 2nd quarter valued at about $689,000. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.